Business Standard

Dr Reddy's facility fails to clear the inspections by USFDA yet again

The fresh round of concerns raised by the USFDA inspectors over the Oncology formulations facility comes as a big setback to the company

Dr Reddy's
Premium

BS Reporter
The Duvvada (Visakhaptanam) sterile injectables facility of drug major Dr Reddy's Laboratories Limited has again been issued a Form 483, this time with 8 observations, by the team of US Food and Drug Administration(USFDA) at the end of the reinspection conducted at the request of the company.

"The audit of our formulations manufacturing facility at Duvvada, Visakhapatnam, by the USFDA, has been completed today. We have been issued a Form 483 with 8 observations, which we are addressing," the company said in a filing.

The fresh round of concerns raised by the USFDA inspectors over the Oncology formulations facility comes

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in